Alimera Sciences, Inc. (ALIM)
USD 5.54
(-0.18%)
USD 5.54
(-0.18%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 7.27 Million USD | 181.44% |
| 2022 | -8.93 Million USD | -475.69% |
| 2021 | 2.37 Million USD | 9.33% |
| 2020 | 2.17 Million USD | 182.61% |
| 2019 | -2.63 Million USD | 62.52% |
| 2018 | -7.02 Million USD | 57.73% |
| 2017 | -13.76 Million USD | 33.74% |
| 2016 | -25.08 Million USD | 31.18% |
| 2015 | -36.44 Million USD | -12.87% |
| 2014 | -32.98 Million USD | 6.15% |
| 2013 | -45.55 Million USD | -56.14% |
| 2012 | -22.03 Million USD | -2.93% |
| 2011 | -21.4 Million USD | 20.31% |
| 2010 | -26.86 Million USD | -634.71% |
| 2009 | 5.02 Million USD | 112.76% |
| 2008 | -39.38 Million USD | -218.4% |
| 2007 | -12.37 Million USD | -20.6% |
| 2006 | -10.25 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 959 Thousand USD | -76.14% |
| 2024 Q2 | 3.03 Million USD | 216.06% |
| 2023 Q4 | 4.22 Million USD | 167.76% |
| 2023 Q3 | -6.23 Million USD | -1047.57% |
| 2023 FY | - USD | 181.44% |
| 2023 Q1 | -2.62 Million USD | -83.93% |
| 2023 Q2 | 658 Thousand USD | 125.1% |
| 2022 Q2 | -1.3 Million USD | 62.29% |
| 2022 Q4 | -1.42 Million USD | 48.13% |
| 2022 Q1 | -3.45 Million USD | -65.22% |
| 2022 Q3 | -2.74 Million USD | -110.66% |
| 2022 FY | - USD | -475.69% |
| 2021 Q4 | -2.09 Million USD | -52.44% |
| 2021 Q2 | 7.63 Million USD | 526.12% |
| 2021 Q1 | -1.79 Million USD | -315.13% |
| 2021 FY | - USD | 9.33% |
| 2021 Q3 | -1.37 Million USD | -117.98% |
| 2020 Q1 | 872 Thousand USD | -58.36% |
| 2020 Q2 | -614 Thousand USD | -170.41% |
| 2020 Q3 | 1.08 Million USD | 276.55% |
| 2020 Q4 | 833 Thousand USD | -23.15% |
| 2020 FY | - USD | 182.61% |
| 2019 Q2 | -2.93 Million USD | -335.61% |
| 2019 Q1 | -674 Thousand USD | -186.86% |
| 2019 Q4 | 2.09 Million USD | 299.81% |
| 2019 FY | - USD | 62.52% |
| 2019 Q3 | -1.04 Million USD | 64.31% |
| 2018 Q3 | -1.55 Million USD | 27.02% |
| 2018 FY | - USD | 57.73% |
| 2018 Q1 | -4.12 Million USD | 18.67% |
| 2018 Q2 | -2.12 Million USD | 48.35% |
| 2018 Q4 | 776 Thousand USD | 149.97% |
| 2017 FY | - USD | 33.74% |
| 2017 Q4 | -5.06 Million USD | 42.71% |
| 2017 Q3 | -8.84 Million USD | -1063.42% |
| 2017 Q2 | -760 Thousand USD | 84.75% |
| 2017 Q1 | -4.98 Million USD | -6.5% |
| 2016 Q4 | -4.68 Million USD | 20.77% |
| 2016 FY | - USD | 31.18% |
| 2016 Q1 | -8.1 Million USD | 10.68% |
| 2016 Q3 | -5.9 Million USD | 10.0% |
| 2016 Q2 | -6.56 Million USD | 18.99% |
| 2015 Q4 | -9.07 Million USD | 43.63% |
| 2015 FY | - USD | -12.87% |
| 2015 Q1 | -12.81 Million USD | 4.1% |
| 2015 Q2 | -11.5 Million USD | 10.21% |
| 2015 Q3 | -16.09 Million USD | -39.85% |
| 2014 Q2 | -13.39 Million USD | -331.79% |
| 2014 Q4 | -13.36 Million USD | -25.88% |
| 2014 Q3 | -10.61 Million USD | 20.74% |
| 2014 Q1 | 5.77 Million USD | 163.57% |
| 2014 FY | - USD | 6.15% |
| 2013 FY | - USD | -56.14% |
| 2013 Q2 | -9.33 Million USD | -13.5% |
| 2013 Q3 | -7.67 Million USD | 17.83% |
| 2013 Q4 | -9.08 Million USD | -18.44% |
| 2013 Q1 | -8.22 Million USD | -0.23% |
| 2012 Q2 | -4.49 Million USD | -9.51% |
| 2012 Q1 | -4.1 Million USD | 29.07% |
| 2012 Q4 | -8.2 Million USD | -58.47% |
| 2012 FY | - USD | -2.93% |
| 2012 Q3 | -5.18 Million USD | -15.32% |
| 2011 FY | - USD | 20.31% |
| 2011 Q3 | -6.23 Million USD | -27.38% |
| 2011 Q2 | -4.89 Million USD | -11.92% |
| 2011 Q1 | -4.37 Million USD | 27.09% |
| 2011 Q4 | -5.78 Million USD | 7.17% |
| 2010 Q2 | -7.36 Million USD | 1.51% |
| 2010 Q1 | -7.48 Million USD | -155.2% |
| 2010 Q4 | -5.99 Million USD | 1.24% |
| 2010 FY | - USD | -634.71% |
| 2010 Q3 | -6.06 Million USD | 17.63% |
| 2009 Q3 | -4.07 Million USD | -10.54% |
| 2009 Q4 | 13.55 Million USD | 432.24% |
| 2009 FY | - USD | 112.76% |
| 2009 Q1 | -759 Thousand USD | -137.93% |
| 2009 Q2 | -3.69 Million USD | -386.17% |
| 2008 Q1 | -33.46 Million USD | 0.0% |
| 2008 FY | - USD | -218.4% |
| 2008 Q3 | -1.76 Million USD | 54.15% |
| 2008 Q2 | -3.83 Million USD | 88.53% |
| 2008 Q4 | -319 Thousand USD | 81.88% |
| 2007 FY | - USD | -20.6% |
| 2007 Q1 | -2.93 Million USD | 0.0% |
| 2007 Q2 | -3.08 Million USD | -4.83% |
| 2006 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 97.64% |
| Embecta Corp. | 245.4 Million USD | 97.035% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 93.344% |
| Dynavax Technologies Corporation | 9.66 Million USD | 24.726% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 104.847% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 95.533% |
| PainReform Ltd. | -9.56 Million USD | 176.037% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -515.567% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 290.251% |
| SCYNEXIS, Inc. | 73.47 Million USD | 90.098% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 409.484% |
| Cosmos Health Inc. | -17.06 Million USD | 142.645% |
| Journey Medical Corporation | 1.92 Million USD | -278.761% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 290.251% |
| Safety Shot Inc | -12.18 Million USD | 159.712% |
| Alpha Teknova, Inc. | -25.53 Million USD | 128.49% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 104.58% |
| Bright Green Corporation | - USD | -Infinity% |
| Procaps Group, S.A. | 104.02 Million USD | 93.006% |
| Theratechnologies Inc. | -10.31 Million USD | 170.553% |
| Harrow Health, Inc. | 9.72 Million USD | 25.167% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 260.796% |
| Biofrontera Inc. | -18.45 Million USD | 139.43% |
| DURECT Corporation | -24.68 Million USD | 129.477% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 92.595% |
| Cronos Group Inc. | -72.14 Million USD | 110.085% |
| OptiNose, Inc. | -15.55 Million USD | 146.782% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 100.787% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 120.165% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 72.299% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 79.806% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 285.501% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 1123.563% |
| Radius Health, Inc. | 38.31 Million USD | 81.008% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 326.309% |
| ProPhase Labs, Inc. | -14.82 Million USD | 149.073% |
| Phibro Animal Health Corporation | 84.6 Million USD | 91.4% |
| Procaps Group S.A. | 104.02 Million USD | 93.006% |
| Alvotech | -484.86 Million USD | 101.501% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 186.609% |
| Viatris Inc. | 3.51 Billion USD | 99.793% |
| Rockwell Medical, Inc. | -4.69 Million USD | 255.006% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 818.972% |
| SIGA Technologies, Inc. | 84.15 Million USD | 91.355% |
| Tilray Brands, Inc. | -72.84 Million USD | 109.989% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -796.059% |
| Shineco, Inc. | -26.55 Million USD | 127.401% |
| PetIQ, Inc. | 81.48 Million USD | 91.071% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 301.126% |
| Incannex Healthcare Limited | -18.5 Million USD | 139.321% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 98.251% |
| Silver Spike Investment Corp. | 7.34 Million USD | 0.873% |
| Assertio Holdings, Inc. | -222.44 Million USD | 103.271% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 282.326% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 272.75% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 143.299% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 136.324% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 104.879% |
| Hempacco Co., Inc. | -12.77 Million USD | 156.963% |
| Talphera, Inc. | -9.84 Million USD | 173.928% |
| Alvotech | -484.86 Million USD | 101.501% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 90.612% |
| Lantheus Holdings, Inc. | 491 Million USD | 98.518% |
| Currenc Group, Inc. | -1.9 Million USD | 482.832% |
| Kamada Ltd. | 21.53 Million USD | 66.212% |
| Indivior PLC | 66 Million USD | 88.976% |
| Evoke Pharma, Inc. | -7.29 Million USD | 199.777% |
| Flora Growth Corp. | -45.87 Million USD | 115.862% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 136.324% |
| Evolus, Inc. | -41.81 Million USD | 117.403% |
| HUTCHMED (China) Limited | 25.52 Million USD | 71.498% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 96.987% |
| Akanda Corp. | -27.73 Million USD | 126.233% |